Meeting
2023 ASCO Annual Meeting
Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Authors
Gordan Srkalovic
Herbert-Herman Cancer Center, Michigan Cancer Research Consortium, Lansing, MI
Gordan Srkalovic , Michael Rothe , Pam K. Mangat , Elizabeth Garrett-Mayer , Eugene R Ahn , Gregory Brouse , John K Chan , Inderjit Mehmi , Maya Khalil , Herbert Leon Duvivier , Anu G. Gaba , Harshraj Leuva , Ramya Thota , Kathleen J Yost , Gina N. Grantham , Abigail Gregory , Dominique C. Hinshaw , Susan Halabi , Richard L. Schilsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT02693535
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3115)
DOI
10.1200/JCO.2023.41.16_suppl.3115
Abstract #
3115
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Charles Drescher
Poster
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
First Author: Susan M. Dombrowski
Poster
2023 ASCO Annual Meeting
Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency.
First Author: Joonoh Lim